Willow Biosciences Stock Probability Of Bankruptcy

WLLW Stock  CAD 0.08  0.01  6.67%   
Willow Biosciences' odds of distress is above 80% at this time. It has very high probability of going through financial hardship in the upcoming years. Odds of distress shows the probability of financial torment over the next two years of operations under current economic and market conditions. All items used in analyzing the odds of distress are taken from the Willow balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Willow Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
  
As of the 12th of December 2024, Market Cap is likely to grow to about 19.8 M. Also, Enterprise Value is likely to grow to about 14.8 M

Willow Biosciences Company odds of distress Analysis

Willow Biosciences' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

 = 

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Willow Biosciences Probability Of Bankruptcy

    
  Over 84%  
Most of Willow Biosciences' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Willow Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Willow Biosciences probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Willow Biosciences odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Willow Biosciences financial health.
Please note, there is a significant difference between Willow Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Willow Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Willow Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Willow Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for Willow Biosciences is extremely important. It helps to project a fair market value of Willow Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Willow Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Willow Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Willow Biosciences' interrelated accounts and indicators.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
Competition

Based on the latest financial disclosure, Willow Biosciences has a Probability Of Bankruptcy of 84%. This is 94.04% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The probability of bankruptcy for all Canada stocks is 110.9% lower than that of the firm.

Willow Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Willow Biosciences' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Willow Biosciences could also be used in its relative valuation, which is a method of valuing Willow Biosciences by comparing valuation metrics of similar companies.
Willow Biosciences is currently under evaluation in probability of bankruptcy category among its peers.

Willow Biosciences Main Bankruptcy Drivers

201920202021202220232024 (projected)
Return On Assets(1.32)(1.55)(0.18)(0.82)(1.95)(2.05)
Net Debt(18.4M)(15.0M)(29.3M)(10.3M)(989K)(1.0M)
Total Current Liabilities1.8M1.6M1.4M1.7M1.8M944.0K
Total Assets33.9M21.9M35.0M18.1M6.7M7.2M
Total Current Assets20.8M17.0M31.3M16.2M4.2M4.5M
Total Cash From Operating Activities(9.2M)(12.8M)(18.2M)(13.9M)(10.9M)(10.4M)

Willow Fundamentals

About Willow Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Willow Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Willow Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Willow Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Willow Biosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Willow Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Willow Biosciences will appreciate offsetting losses from the drop in the long position's value.

Moving together with Willow Stock

  0.83CMC Cielo Waste Solutions Earnings Call This WeekPairCorr

Moving against Willow Stock

  0.79LQWD LQwD FinTech CorpPairCorr
  0.76MATE Blockmate VenturesPairCorr
The ability to find closely correlated positions to Willow Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Willow Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Willow Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Willow Biosciences to buy it.
The correlation of Willow Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Willow Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Willow Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Willow Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Willow Stock

Willow Biosciences financial ratios help investors to determine whether Willow Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Willow with respect to the benefits of owning Willow Biosciences security.